Vaccines and antidiabetics lead the charge for Japanese market growth
This article was originally published in Scrip
Japan's prescription market rose by a solid 7.7% to ¥2,332.3 billion ($30.25 billion) at official reimbursement prices in the July-September quarter, helped by the lack of a regular biennial price cut in April and strong growth for antidiabetics and vaccines.
You may also be interested in...
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.